Introduction

Multiple sclerosis (MS) is a chronic inflammatory disease of central nervous system (CNS) that affects more than 2.5 million people worldwide. In MS, inflammation, demyelination and neurodegeneration are considered to contribute to disease development. It is assumed that in MS, a misguided immune response against the CNS is initiated and orchestrated by autoreactive T cells, leading to progressive demyelination, oligodendrocyte injury and axonal loss, that affect not only the white but also the grey matter.

The mechanisms by which neuroinflammation and myelin damage lead to neurodegeneration have not been fully elucidated; however, the sustained release of reactive oxygen species (ROS) and nitrogen species (NOS) by macrophages and activated microglia during inflammation appears to contribute to the damaging cascade. Also in cortical lesions, demyelination appears to be associated with excessive oxidative damage. Mitochondrial pathology and subsequent focal axonal injury appears also to be triggered by inflammation-associated ROS and NOS and to
be independent of demyelinating processes.\textsuperscript{11} Axonal mitochondrial damage is an early sign of neurodegeneration that precedes and contributes to focal and reversible alterations in axon morphology. The alterations of the mitochondrial function within axons have been proposed to occur in the early stages of the disease, even before demyelination,\textsuperscript{11,12} and to precede neuronal death.\textsuperscript{13–16} In autopsied tissue from chronic progressive MS, respiratory deficient neurons were detected both in white and grey matter. Respiration deficits were shown to be caused by multiple deletions of mitochondrial DNA, probably subsequent to inflammation and oxidative stress, that contributed to an enhanced susceptibility of axons and neurons to additional damaging insults.\textsuperscript{17} In this line, we and others have shown that oxidative stress disrupts the transport of mitochondria in the axon.\textsuperscript{14,18} Hence, mitochondrial dysfunction is considered as one of the major contributors of neuroaxonal damage in MS.

With regard to MS management and treatment, teriflunomide (TFN) (Aubagio; Genzyme, Cambridge, MA, USA) is a once-daily oral immunomodulatory drug for the treatment of patients with relapsing forms of MS.\textsuperscript{19} TFN has been shown to reduce relapse events and increase the periods of remission.\textsuperscript{20,21}

TFN seems to exert its therapeutic effect by non-competitively and reversibly inhibiting the mitochondrial respiratory chain-associated enzyme dihydroorotate dehydrogenase (DHODH).\textsuperscript{22–25} DHODH is involved in \textit{de novo} pyrimidine biosynthesis, thus limiting lymphocytic proliferation and inflammation. However, whether the inhibition of DHODH alone may affect neuronal mitochondria remains uncertain. Importantly, a very recent retrospective, single-center, observational study indicated that the effect of TFN in reducing cortical grey matter atrophy is superior to the effect of the anti-oxidative and anti-inflammatory dimethyl fumarate.\textsuperscript{26} Moreover, it has been reported that TFN penetrates into the CNS and exerts its effect directly within the brain.\textsuperscript{27} Thus, TFN may indeed have the potential to affect axonal mitochondria directly.

To explore the possible effects of TFN on the nervous system, we have used in this study a previously established model of explanted spinal roots, in which we had shown that mitochondria undergo a series of alterations in response to oxidative stress.\textsuperscript{18,28}

In patients treated daily with 14 mg TFN, average steady-state maximum TFN concentration (\(C_{\text{max}}\)) in plasma is 168 \(\mu\text{M}\).\textsuperscript{29} The half maximum concentration (\(IC_{50}\)) for interaction of TFN with human DHODH is 1 \(\mu\text{M}\)\textsuperscript{30,31} and 50–100 \(\mu\text{M}\) is considered sufficient to inhibit protein tyrosine kinase \textit{in vitro}.\textsuperscript{29,31} Moreover, a study assessing the effect of TFN on erythropoiesis indicated that concentrations ranging from 3.7 to 37 \(\mu\text{M}\) TFN might compensate oxidative stress-mediated erythrocyte changes \textit{in vitro}.

In rats, it has been shown that after one single injection of 10 \(\mu\text{g/g}\) TFN, approximately 2–4\% of the blood concentration was found in the CNS.\textsuperscript{32} After injection of 100 \(\mu\text{g/g}\), it has been reported that TFN penetrates into the CNS and exerts its effect directly within the brain (\(25\pm1.3\%\)).\textsuperscript{32} Although an extrapolation to the human reality is not exact, we could suppose in treated patients a TFN concentration within the nervous system of about 3–7 \(\mu\text{M}\). Therefore, in our study, we investigated the effect of TFN on oxidative stress-induced mitochondrial alterations in murine root explants using three different TFN concentrations, 1 \(\mu\text{M}\), 5 \(\mu\text{M}\) and 50 \(\mu\text{M}\).

We show that TFN is able to prevent mitochondrial alterations induced by hydrogen peroxide (\(\text{H}_2\text{O}_2\)), suggesting that TFN has additional therapeutically relevant properties related to mitochondrial protection in axons.\textsuperscript{31}

\section*{Materials and methods}

\subsection*{Ethics}

All experimental procedures were approved by the local authority on animal studies in Berlin (Landesamt für Gesundheit und Soziales Berlin; ID: T0002/10). Animal studies were performed in strict accordance with the European Communities Council Directive of 22 September 2010 (2010/63/EU).

\subsection*{Solutions and drugs}

Explanted roots were bathed in artificial cerebrospinal fluid (aCSF) containing the following: solution I: 124 mM sodium chloride (NaCl), 1.25 mM sodium dihydrogen phosphate (\(\text{NaH}_2\text{PO}_4\)), 10.0 mM glucose, 1.80 mM magnesium sulphate (\(\text{MgSO}_4\)), 1.60 mM calcium chloride (\(\text{CaCl}_2\)), 3.00 mM potassium chloride (KCl);...
solution II: 26.0 mM sodium bicarbonate (NaHCO₃). Solutions I and II were mixed immediately before use. Hydrogen peroxide (H₂O₂; 30% w/w in H₂O, with a stabilizer) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. To induce oxidative stress, explanted roots were incubated with 50 µM of H₂O₂ dissolved in aCSF for 30 min. TFN was applied at different concentrations along with H₂O₂ for 30 min. TFN was provided in powder form by the manufacturer (Sanofi Genzyme), which was dissolved in DMSO and stored at −20°C.

Preparation of ventral spinal roots

Ventral spinal roots were prepared as described in our previous work. Briefly, C57BL/6 mice at least 3 weeks of age were anesthetized with isoflurane prior to cervical dislocation. After separating the connective tissue and exposing the dorsal side of the spinal cord, an initial sectioning was made at the thoracic level, which proceeded in a rostral to caudal direction until the last vertebrae. The spinal cord was lifted gently to expose the ventral roots, which were cut distal to the spinal cord but before the formation of the peripheral nerves. The explanted spinal cord with attached roots was transferred to aCSF saturated with carbogen (95% oxygen [O₂]; 5% carbon dioxide [CO₂]). Under a dissecting microscope, lumbar ventral roots of at least 0.8 cm were selected and separated from the spinal cord.

Labeling of mitochondria

All experimental incubations were conducted in a submerged incubation chamber (Brain Slice Keeper- BSK6-6; Scientific Systems Design Inc., Ontario, Canada), which allows for multiple treatment conditions and continuous carbogen perfusion of each submersion well. Transected ventral spinal roots were transferred to fresh aCSF saturated with carbogen (95% oxygen [O₂]; 5% carbon dioxide [CO₂]). Under a dissecting microscope, lumbar ventral roots of at least 0.8 cm were selected and separated from the spinal cord.

Confocal microscopy

Explanted ventral roots were placed onto a glass coverslip and transferred to an imaging chamber filled with carbogenated aCSF. To prevent movement of the roots during imaging, a custom-built net was placed on the top of the roots. For all imaging experiments, we used an inverted laser-scanning confocal microscope adapted for live cell imaging (LSM 710; Carl Zeiss, Jena, Germany). MitoTracker Orange was excited with a diode-pumped solid state (DPSS) laser at 561 nm. After finding the middle of the root, 3 × 60-sec videos (2 sec/frame) with a resolution of 512 × 512 pixels were acquired in three separate regions of interest (ROI) according to the following criteria: (a) there was a clearly defined node of Ranvier; (b) there were visibly labeled mitochondria; and (c) the areas were no closer than 0.2 cm from the ends of the roots. Typically, the first ROI was located at the middle of the root, whereas the following two were to the right and left of the middle region.

Analysis of mitochondrial dynamics

Mitochondrial morphology was assessed using an automated analysis function of the Volocity 6.3 software (Perkin Elmer, Rodgau, Germany). The first frame of every video was used for analysis. Shape factor, a measure of circularity ranging from 0 and 1 (closer to ‘0’ was a longer mitochondrion, whereas ‘1’ was a perfect circle), length (µm) and area of individual mitochondria were quantified for assessing change in mitochondrial morphology.

Mitochondrial transport was quantified in terms of the number of moving mitochondria, velocity, displacement, and track length of moving mitochondria. Displacement is the measure of shortest distance in µm, covered by a mitochondrion; it was measured as a straight line from the start to the end position during the 30 frames. Track length is the measure of real distance path longitude followed by the mitochondrion. Mitochondria were tracked manually using Volocity 6.3 software (Perkin Elmer, Rodgau, Germany). Any mitochondrion with a displacement of at least 1 µm was considered ‘mobile’. Measurements from three ROI were averaged for each root.

In total, 15 different mice in 15 independent experiments were investigated. Depending on the quality of the explants, at least five independent roots and 15 ROI per culturing condition were included into the analysis (usually up to three different ROI per root). Specifically, 39 and 44 ROI were analyzed for the untreated group and H₂O₂ treated groups, respectively; 15–21 ROI were used to investigate treatments with H₂O₂ + TFN.
For the morphological investigations, the number of mitochondria in the selected ROI were 2586, 2860, 1306, 875 and 1550 for untreated, H_2O_2-treated, H_2O_2+TFN (1 µM), H_2O_2+TFN (5 µM) and H_2O_2+TFN (50 µM), respectively. Analyses of motility included 201, 70, 83, 52 and 64 motile mitochondria for each of the above-mentioned groups.

For the comparison of untreated versus TFN-treated nerves, four independent experiments were performed. Analyses include 12 ROI per condition. In total, 568 and 672 individual mitochondria were analyzed, respectively.

Quantification of relative change in intracellular ROS
The fluorescence intensity of the MitoTracker Orange was quantified as a measure of intracellular ROS as described by Kweon et al.,34 The images obtained from confocal microscopy were used for the quantification of mitochondrial fluorescence intensity using Image J software.

Statistical analysis and data representation
The data were analyzed with Prism 5.01 software (GraphPad, CA, USA). All datasets were subjected first to D’Agostino and Pearson omnibus K2 normality test for Gaussian distribution. All data fitting the criteria for a normal distribution were subsequently analyzed using a one-way analysis of variance (ANOVA) with Bonferroni’s post hoc test. All data following a non-parametric distribution were analyzed using a Kruskal–Wallis test followed by a post hoc Dunn’s multiple comparisons test. All data are given in mean ± SD.

Data are shown in Tukey box and whisker plots. The box and whisker plot shows simultaneously the minimum, first quartile, mean (+), median (dissecting line inside the box), third quartile, and maximum of the data set. Whiskers indicate variability outside the upper and lower quartiles. Outliers are plotted as individual dots that are in line with whiskers. The mean ± SD values are given in the corresponding tables.

Results
TFN altered mitochondrial dynamics in peripheral root explants
We labelled peripheral root mitochondria with MitoTracker Orange and the explants were imaged for morphological investigation (Figure 1a, b). Then, the effects of TFN on mitochondrial morphology and transport in unmanipulated explanted roots were investigated. Explanted roots were
incubated in the presence or absence of 50 µM TFN. TFN treatment resulted in a statistically significant decrease in mitochondrial circularity (Figure 1c) and an increase in mitochondrial length (Figure 1d). There were no significant changes in mitochondrial area (Figure 1e) after TFN treatment compared with the untreated controls. For mitochondrial motility, TFN did not significantly change the number of motile mitochondria (Figure 2a) as well as the distance covered by the mitochondria (Figure 2c, d). However, it induced a significant reduction of the mean velocity of mitochondrial transport (Figure 2b). Corresponding statistical information is summarized in Table 1.

**TFN prevented oxidative stress-induced morphological changes in mitochondria**

We previously reported that oxidative stress leads to substantial changes to both morphology and transport of axonal mitochondria. Here, we investigated whether TFN, applied together with H$_2$O$_2$, would be able to prevent these effects. We treated the roots with 50 µM H$_2$O$_2$ (both groups containing the vehicle DMSO), and 3 different concentrations of TFN: 1, 5 and 50 µM in aCSF (Figure 3a–e). We analyzed a total of 39 untreated ROI, 44 ROI treated with H$_2$O$_2$, and 18, 15 and 21 ROI treated with 1 µM, 5 µM and 50 µM TFN in the presence of 50 µM H$_2$O$_2$, respectively, from 15 independent experiments. Consistent with our previous findings, we observed that treatment with 50 µM H$_2$O$_2$ induced an overall increase of mitochondrial circularity and a corresponding decrease in mitochondrial length and area. In particular, mitochondria were significantly more circular (Figure 3f), shorter (Figure 3g) and smaller (Figure 3h) than their untreated counterparts.

In the presence of 1 µM TFN, the shape factor of the mitochondria was reduced, that is,
**Table 1.** Summary of morphology and motility parameters of mitochondria in untreated and teriflunomide-treated peripheral root explants.

|                | n=  | Shape factor | Length (µm) | Area (µm²) | No. of motile mitochondria | Velocity (µm/s) | Trajectory length (µm) | Displacement (µm) |
|----------------|-----|--------------|-------------|------------|---------------------------|-----------------|------------------------|-------------------|
| Untreated      | 39  | 0.52 ± 0.21  | 1.75 ± 1.52 | 0.77 ± 0.86 | 4.72 ± 1.67               | 0.36 ± 0.07     | 7.77 ± 3.26            | 5.46 ± 2.39       |
| TFN [50 µM]    | 12  | 0.48 ± 0.23  | 1.89 ± 1.67 | 0.66 ± 0.82 | 3.83 ± 2.06               | 0.24 ± 0.15     | 5.51 ± 3.49            | 3.71 ± 2.43       |
| Mann–Whitney test |    | **>0.1**  | *           | >0.1       | *                         | >0.1            | >0.1                   |                   |

Values are shown as mean ± SD.

*p < 0.05; **p < 0.01

**Figure 3.** Mitochondrial morphology altered during oxidative stress with/out teriflunomide (TFN) treatment. Representative image of mitochondria in (a) untreated, (b) hydrogen peroxide (H₂O₂)-treated, and (c, d, and e) H₂O₂-TFN-treated, where TFN was 1, 5 and 50 µM, respectively, in murine peripheral root explants. Scale bar: 10 µm. (f) Change in mitochondrial shape factor, (g) length, and (h) area of mitochondria in the presence of H₂O₂ with or without TFN.

Graphs are shown in Tukey boxplots, where the central line denotes the median; the lower and upper boundaries denote the 1st and 3rd quartile, and the whiskers denote the spread of the data. Inside the box, ‘+' delineates the mean.

*p < 0.05, **p < 0.01, ***p < 0.001.
mitochondria became elongated or rod-shaped (Figure 3f). In contrast, no effects were observed at higher concentration of TFN. Moreover, the lowest and highest TFN concentrations (1 µM and 50 µM) induced a significant increase in mitochondrial length (Figure 3g) and area (Figure 3h), in comparison with the mitochondria exposed to H2O2 alone. Paradoxically, treatment with 5 µM TFN with 50 µM H2O2 showed no statistically significant effect on H2O2-induced morphological alterations (Figure 3f–h) (0.59 ± 0.19 shape factor, 1.43 ± 1.29 µm length, and 0.51 ± 0.69 µm² area; Kruskal-Wallis test followed by Dunn’s post hoc test \( p > 0.1 \) in all cases).

Corresponding statistical information is summarized in Table 2.

### Table 2. Summary of shape factor, length and area of mitochondria under H2O2 treatment alone, and with 50 µM H2O2 in the presence of 1 µM, 5 µM and 50 µM teriflunomide.

|          | n  | Shape factor | KW test | Length (µm) | KW test | Area (µm²) | KW test |
|----------|----|--------------|---------|-------------|---------|------------|---------|
| Untreated| 39 | 0.53 ± 0.22  | ***     | 1.82 ± 1.79 | ***     | 0.69 ± 0.92 | ***     |
| H2O2-treated | 44 | 0.58 ± 0.21  |         | 1.49 ± 1.29 |         | 0.57 ± 0.65 |         |
| H2O2 + TFN (1 µM) | 18 | 0.57 ± 0.21  | *      | 1.66 ± 1.50 | **      | 0.67 ± 0.85 | **      |
| H2O2 + TFN (5 µM) | 15 | 0.59 ± 0.19  | >0.1   | 1.43 ± 1.29 | >0.1   | 0.51 ± 0.69 | >0.1   |
| H2O2 + TFN (50 µM) | 21 | 0.59 ± 0.21  | >0.1   | 1.66 ± 1.42 | ***     | 0.75 ± 0.93 | ***     |

KW, Kruskal–Wallis; H2O2, hydrogen peroxide.
Values are shown as mean ± SD.
* \( p < 0.05 \); ** \( p < 0.01 \); *** \( p < 0.001 \).

Again, the lowest and highest TFN concentration (1 µM and 50 µM) restored the motility-related parameters to control levels, except for the mitochondrial velocity with 50 µM TFN, when compared with the mitochondria exposed to H2O2 alone; for the number of moving mitochondria (Figure 4f), velocity (Figure 4g), trajectory (Figure 4h), and displacement (Figure 4i). In contrast, 5 µM TFN had no effect. Corresponding statistical information is summarized in Table 3.

### TFN prevented change in mitochondrial oxidation potential in peripheral nerve explants during oxidative stress

MitoTracker Orange CMTMRos is a reduced, non-fluorescent dye that fluoresces on oxidation. Thus, in conditions of high oxidative stress, mitochondria acquire higher fluorescence intensity.34 We observed that fluorescence intensity was higher in H2O2-treated roots compared with untreated controls (Figure 5). In the presence of 1 µM TFN, the fluorescence intensity in the mitochondria was reduced, approaching the values of the untreated axons (Table 4), suggesting that the H2O2-mediated increase in the oxidation potential could be prevented by TFN. In contrast, no effect was observed at 5 or 50 µM TFN. Corresponding statistical information is summarized in Table 4.

### Discussion

While current treatments for MS focus on reducing inflammation via modulation of the
Figure 4. Mitochondrial motility altered during oxidative stress with or without teriflunomide (TFN) treatment. A representative image of mitochondrial tracking in (a) untreated, (b) hydrogen peroxide [H$_2$O$_2$]-treated, and (c, d, and e) H$_2$O$_2$-TFN treated where TFN was 1, 5 and 50 µM, respectively, in murine peripheral root explants. (f) Number, (g) velocity, (h) trajectory, and (i) displacement of mitochondria. Graphs are shown in Tukey boxplots, where the central line denotes the median; the lower and upper boundaries denote the first and third quartile and the whisks denote the spread of the data. Inside the box, ‘+’ delineates the mean. *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 5. Teriflunomide (TFN) at 1 µM altered the oxidation potential of mitochondria, reducing oxidative MitoTracker Orange fluorescence intensity. Fluorescence intensity of MitoTracker Orange staining depicting significant reduction of oxidation potential of 1 µM TFN. (b) MitoTracker Orange fluorescence intensity at 1, 5 and 50 µM TFN treatment during oxidative stress in comparison with untreated and H$_2$O$_2$-treated roots.

*Statistical significance with \( p < 0.05 \).

Table 3. Summary of mitochondrial motility, velocity, displacement and trajectory length under H$_2$O$_2$ treatment alone, and along with different concentrations of teriflunomide.

|       |  \# motile mitochondria (axon) | Velocity (µm/s) | Trajectory length (µm) | Displacement (µm) |
|-------|---------------------------------|-----------------|------------------------|-------------------|
| Untreated | 39 | 4.85 ± 3.72 [39] | 0.29 ± 0.14 | 6.77 ± 3.13 | 4.59 ± 2.16 |
| H$_2$O$_2$-treated | 44 | 1.52 ± 1.71 [39] | 0.15 ± 0.14 | 3.53 ± 3.67 | 2.30 ± 2.60 |
| H$_2$O$_2$ + TFN (1 µM) | 18 | 4.71 ± 3.08 [21] | 0.30 ± 0.13 | 6.13 ± 2.59 | 4.37 ± 1.97 |
| H$_2$O$_2$ + TFN (5 µM) | 15 | 3.08 ± 2.75 [12] | >0.1 | 5.61 ± 3.69 | 3.87 ± 2.96 |
| H$_2$O$_2$ + TFN (50 µM) | 21 | 4.27 ± 2.34 [15] | >0.1 | 6.84 ± 2.15 | 4.75 ± 1.45 |

KW, Kruskal–Wallis; H$_2$O$_2$, hydrogen peroxide.

Values are shown as mean ± SD.

\*\( p < 0.05 \); \**\( p < 0.01 \); \***\( p < 0.001 \).

Table 4. Summary of mean fluorescence intensities of mitochondria.

|       | MitoTracker fluorescence (AU) | Mann–Whitney test |
|-------|-------------------------------|-------------------|
| Untreated | 39 | 7.35 ± 4.76 | * |
| H$_2$O$_2$-treated | 44 | 11.49 ± 6.44 | |
| H$_2$O$_2$ + TFN (1 µM) | 18 | 7.48 ± 2.75 | * |
| H$_2$O$_2$ + TFN (5 µM) | 15 | 10.22 ± 6.45 | >0.1 |
| H$_2$O$_2$ + TFN (50 µM) | 21 | 11.27 ± 4.79 | >0.1 |

AU, arbitrary units.

Values are shown as mean ± SD.

\*\( p < 0.05 \).
immune system, there is a general lack of treatment targeting inflammation-promoted neurodegeneration, which is an integral component of disability progression. As early mitochondrial alterations are reported in inflammatory neurodegenerative diseases, the maintenance of mitochondrial integrity could be a key goal to achieve neuronal protection during neuroinflammation. Here, we hypothesized that TFN, due to its ability to inhibit DHODH, an enzyme functionally linked with complex III activity of the mitochondrial respiratory chain, may influence mitochondrial stability in the context of oxidative stress. To test our hypothesis, we used our previously established model of murine explanted ventral roots, in which the morphology and the transport of mitochondria can be analyzed within peripheral axons.

After excluding any relevant effect of DMSO (the dilution vehicle), in both untreated and H2O2-treated mitochondria (Supplemental Figures 1–2), we investigated the effect of TFN treatment in unmanipulated or oxidative stress-exposed spinal root explants.

Interestingly, in non-stressed roots, TFN seems to promote mitochondrial fusion, induce mitochondrial elongation (Figure 1d, e), and reduce mitochondrial velocity (Figure 2b). Mitochondrial fusion is important for the formation of mitochondrial networking that assists in reshuffling and redistributing the mitochondrial content. Thus, the inhibition of DHODH and subsequent effects on complex III of the electron transport chain and respiration may promote mitochondrial fusion as an attempt to redistribute the electron transport complexes that are still capable of maintaining the proton gradient and synthesizing adenosine triphosphate (ATP).

In contrast, during oxidative stress, we observed a reduction in mitochondrial length and size, which is indicative of fragmentation/fission of mitochondria that might undergo mitophagy. Mitochondrial fission has also been proposed to increase the number of mitochondria and their cellular distribution in order to meet the increasing energy demands of the cell. Although mitochondrial fission is extensively discussed in terms of mitophagy as well as apoptosis, intensive mitochondrial fission may translate into mitochondrial failure and the strategy to optimize mitochondrial functionality before undergoing apoptosis. It also serves to get rid of damaged, irreparable mitochondrial parts. Importantly, in the presence of 1 µM and 50 µM TFN, reduction in mitochondrial length and area due to oxidative insult could be prevented (Figure 3g, h). Intensive fragmentation during oxidative stress could not be prevented with 5 µM TFN.

Further, consistent with previous findings, we observed a reduced mitochondrial motility during oxidative stress, that is, reduced trajectories and transport velocity. The impairment of mitochondrial transport was preserved with TFN treatment. In axons, around 10–30% of mitochondria are motile, while more than 70% remain stationary. This motile and stationary pool of mitochondria is dependent on the current energy demands of the cell. In addition, disrupted motility could lead to impairment of mitochondrial fusion. Thus, TFN may promote fusion by influencing the motility. On the other hand, it has been proposed that inhibition of DHODH by TFN may reduce the total amount of ROS in the cell. Although mitochondrial fission is extensively discussed in terms of mitophagy as well as apoptosis, intensive mitochondrial fission may translate into mitochondrial failure and the strategy to optimize mitochondrial functionality before undergoing apoptosis. It also serves to get rid of damaged, irreparable mitochondrial parts. Importantly, in the presence of 1 µM and 50 µM TFN, reduction in mitochondrial length and area due to oxidative insult could be prevented (Figure 3g, h). Intensive fragmentation during oxidative stress could not be prevented with 5 µM TFN.

Along this line, to assess the effects of TFN on ROS in our system, we monitored the fluorescence intensity of MitoTracker Orange CMTMRos (see Methods). As expected, fluorescence intensity of CMTMRos significantly increased with H2O2 treatment, while inhibition of DHODH with 1 µM TFN reduced the ROS level (Figure 5). As complex III of the ETC is considered one of the major contributors to ROS formation, its compromised activity in the presence of TFN might reduce ROS production in mitochondria in peripheral spinal root explants. 5 µM and 50 µM TFN could not effectively reduce ROS, which might be attributed to the inhibition at higher concentrations of additional signaling pathways including tyrosine kinases.

On the other hand, the intermediate dose of 5 µM TFN showed no effects on H2O2-induced shape or motility changes. Why, in our experimental setup a dose effect is missing, remains uncertain. The high variability of our data, which is intrinsic to the nature of mitochondrial dynamics and reflects the heterogeneity of the mitochondrial population in both physiological and diseased conditions, could have contributed to mask a true dose effect. To minimize this problem, several experiments
with large amounts of mitochondria were analyzed (see Methods section). Moreover, depending on its concentration, TFN may function by a different mode of action. While low TFN concentrations are effective in inhibiting DHODH (1–1.5 µM), concentrations needed to achieve DHODH-independent effects such as inhibition of protein tyrosine kinase or cyclooxygenase-2 are much higher (50–200 µM).29 However, little is known about the mode of action of intermediate concentrations. One could speculate that in our model, TFN at 5 µM may achieve partially known or yet undefined DHODH-independent effects that rather counterbalance the beneficial effects observed at 1 µM, while at 50 µM DHODH-dependent and independent mechanisms may synergize against dysfunctions observed under oxidative stress. Future experiments using long-living explants are needed to evaluate to what extent TFN effects at different concentration are DHODH-dependent and thus reversible.

Our previous data on root explants demonstrated that mitochondrial alterations caused by oxidative stress precede axonal damage.18 Now, we show that these alterations could be pharmaco logically reversed in vitro by TFN. Targeting dysfunction of axonal mitochondria should become one of the key goals in drug development not only for MS but also for other classic neurodegenerative disorders such as Parkinson’s or Alzheimer diseases.54 In this line, we showed in the animal model of MS a protective effect of epigallocatechin-3-gallate (EGCG),55,56 a polyphenol, that among others, inhibits the formation of ROS and protects neurons.57,58 Also dimethyl fumarate, used to treat MS, prevents oxidative stress-related mitochondrial dysfunction, apoptosis and autophagy in murine oligodendrocytes in vitro.59 Importantly, endogenous substances currently being investigated in MS may be exploited as therapeutics due their mitochondrial protective capacities, such as high dose biotin,60 vitamin D61 or octadecaneuropeptide, a neurotrophic peptide produced principally by astrocytes, which is able to counteract oxidative stress-induced alterations.62

In summary, our present findings suggest a protective effect of TFN on axonal mitochondria exposed to oxidative stress. Investigations expanding on these findings are needed to determine whether mitochondrial protection at the axonal level can be translated into protection of axons and neurons.

Conflict of interest
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by a research grant from Sanofi Genzyme to C.I-D. A.E.H., was supported by DFG TRR130, TP17. The authors also acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Funds of Charité-Universitätsmedizin.

ORCID iD
Carmen Infante-Duarte https://orcid.org/0000-0003-3005-351X

Supplemental material
Supplemental material for this article is available online.

References
1. Chen AY, Chonghasawat AO and Leadholm KL. Multiple sclerosis: frequency, cost, and economic burden in the United States. J Clin Neurosci 2017; 45: 180–186.
2. Compston A and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502–1517.
3. Dutta R and Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007; 68 (Suppl. 3): S22–S31; discussion S43–S54.
4. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–286.
5. Mäurer M and Rieckmann P. Relapsing–remitting multiple sclerosis: what is the potential for combination therapy? BioDrugs 2000; 13: 149–158.
6. Geurts JJG and Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7: 841–851.
7. Barsukova AG, Forte M and Bourdette D. Focal increases of axoplasmic Ca²⁺, aggregation of sodium-calcium exchanger, N-type Ca²⁺ channel, and actin define the sites of spheroids in axons undergoing oxidative stress. J Neurosci 2012; 32: 12028–12037.
8. Coleman M. Axon degeneration mechanisms: commonality amid diversity. *Nat Rev Neurosci* 2005; 6: 889–898.

9. Mossakowski AA, Pohlan J, Bremer D, et al. Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation. *Acta Neuropathol* 2015; 130: 799–814.

10. Fischer MT, Wimmer I, Höftberger R, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. *Brain* 2013; 136: 1799–1815.

11. Nikić I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. *Nat Med* 2011; 17: 495–499.

12. Mahad D, Ziabreva I, Lassmann H, et al. Mitochondrial defects in acute multiple sclerosis lesions. *Brain* 2008; 131: 1722–1735.

13. Court FA and Coleman MP. Mitochondria as a central sensor for axonal degenerative stimuli. *Trends Neurosci* 2012; 35: 364–372.

14. Fang C, Bourdette D and Banker G. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. *Mol Neurodegener* 2012; 7: 29.

15. Medana IM and Esiri MM. Axonal damage: a key predictor of outcome in human CNS diseases. *Brain* 2003; 126: 515–530.

16. Saxton WM and Hollenbeck PJ. The axonal transport of mitochondria. *J Cell Sci* 2012; 125: 2095–2104.

17. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. *Ann Neurol* 2011; 69: 481–492.

18. Bros H, Millward JM, Paul F, et al. Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons. *Exp Neurol* 2014; 261: 127–135.

19. Armstrong JA, Cash NJ, Ouyang Y, et al. Oxidative stress alters mitochondrial bioenergetics and modifies pancreatic cell death independently of cyclophilin D, resulting in an apoptosis-to-necrosis shift. *J Biol Chem* 2018; 293: 8032–8047.

20. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol* 2014; 13: 977–986.

21. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med* 2011; 365: 1293–1303.

22. Bar-Or A. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. *Exp Neurol* 2014; 262: 57–65.

23. Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. *J Neuroimmunol* 2013; 265: 82–90.

24. Warnke C, zu Hörste GM, Hartung HP, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. *Neuropsychiatr Dis Treat* 2009; 5: 333–340.

25. Warnke C, Stüve O and Kieseier BC. Teriflunomide for the treatment of multiple sclerosis. *Clin Neurol Neurosurg* 2013; 115 (Suppl. 1): S90–S94.

26. Zivadinov R, Bergslund N, Carl E, et al. Effect of teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: a retrospective, observational, case–control pilot study. *J Clin Med* 2019; 8: 344.

27. Rzagalinski I, Hainz N, Meier C, et al. Spatial and molecular changes of mouse brain metabolism in response to immunomodulatory treatment with teriflunomide as visualized by MALDI-MSI. *Anal Bioanal Chem* 2019; 411: 353–365.

28. Bros H, Millward JM, Paul F, et al. An ex vivo model for studying mitochondrial trafficking in neurons. *Methods Mol Biol* 2015; 1264: 465–472.

29. Oh J and O’Connor PW. An update of teriflunomide for treatment of multiple sclerosis. *Ther Clin Risk Manag* 2015; 1264: 465–472.

30. Kaplan J, Cavalier S and Turpault S. Biodistribution of teriflunomide in naive rats vs rats with experimental autoimmune encephalomyelitis. *ECTRIMS Online Library*, 2015.

31. Palmer AM. Efficacy and safety of teriflunomide in treatment of multiple sclerosis. *J Symptoms Signs* 2013; 2: 444–457.

32. Zierle J, Bissinger R and Lang F. Inhibition by teriflunomide of erythrocyte cell membrane scrambling following energy depletion, oxidative stress and ionomycin. *Cell Physiol Biochem* 2016; 39: 1877–1890.
33. Bros H, Hauser A, Paul F, et al. Assessing mitochondrial movement within neurons: manual versus automated tracking methods. Traffic 2015; 16: 906–917.

34. Kweon SM, Kim HJ, Lee ZW, et al. Real-time measurement of intracellular reactive oxygen species using mito tracker orange (CMH2TMRos). Biosci Rep 2001; 21: 341–352.

35. Breedveld FC and Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841–849.

36. Claussen MC and Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012; 142: 49–56.

37. Rudick RA and Trapp BD. Gray-matter injury in multiple sclerosis. N Engl J Med 2009; 361: 1505–1506.

38. Aktas O, Smorodchenko A, Brocke S, et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005; 46: 421–432.

39. Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010; 1802: 212–220.

40. Fang J, Uchiumi T, Yagi M, et al. Dihydroorotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction. Biosci Rep 2013; 33: e00021.

41. Khutornenko AA, Dalina AA, Chernyak BV, et al. The role of dihydroorotate dehydrogenase in apoptosis induction in response to inhibition of the mitochondrial respiratory chain complex III. Acta Naturae 2014; 6: 69–75.

42. Rafelski SM. Mitochondrial network morphology: building an integrative, geometrical view. BMC Biol 2013; 11: 71.

43. Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet 2012; 46: 265–287.

44. Kaasik A, Safiulina D, Choubey V, et al. Mitochondrial swelling impairs the transport of organelles in cerebellar granule neurons. J Biol Chem 2007; 282: 32821–32826.

45. Safiulina D and Kaasik A. Energetic and dynamic: how mitochondria meet neuronal energy demands. PLoS Biol 2013; 11: e1001755.

46. Detmer SA and Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 2007; 8: 870–879.

47. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006; 125: 1241–1252.

48. Misgeld T, Kerschensteiner M, Bareyre FM, et al. Imaging axonal transport of mitochondria in vivo. Nat Methods 2007; 4: 559–561.

49. Schwarz TL. Mitochondrial trafficking in neurons. Cold Spring Harb Perspect Biol 2013; 5: a011304.

50. Ohno N, Kidd GJ, Mahad D, et al. Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier. J Neurosci 2011; 31: 7249–7258.

51. Cagalinec M, Safiulina D, Liiv M, et al. Principles of the mitochondrial fusion and fission cycle in neurons. J Cell Sci 2013; 126: 2187–2197.

52. Fairus AKM, Choudhary B, Hosahalli S, et al. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells. Biochimie 2017; 135: 154–163.

53. Herrmann ML, Schleyerbach R and Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47: 273–289.

54. Area-Gomez E, Guardia-Laguarta C, Schon EA, et al. Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas. J Clin Invest 2019; 129: 34–45.

55. Janssen A, Fiebig S, Bros H, et al. Treatment of chronic experimental autoimmune encephalomyelitis with epigallocatechin-3-gallate and glatiramer acetate alters expression of heme-oxygenase-1. PLoS One 2015; 10: e0130251.

56. Herges K, Millward JM, Hentschel N, et al. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One 2011; 6: e25456.

57. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004; 173: 5794–5800.

58. Schroeder EK, Kelsey NA, Doyle J, et al. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal 2009; 11: 469–480.
attenuate oxidative stress and mitochondrial alterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. *J Steroid Biochem Mol Biol* 2019; 194: 105432.

60. Sedel F, Bernard D, Mock DM, *et al.* Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. *Neuropharmacology* 2016; 110: 644–653.

61. Rodney C, Rodney S and Millis RM. Vitamin D and demyelinating diseases: neuromyelitis optica (NMO) and multiple sclerosis (MS). *Autoimmune Dis* 2020; 2020: 8718736.

62. Namsi A, Nury T, Khan AS, *et al.* Octadecaneuropeptide (ODN) induces N2a cells differentiation through a PKA/PLC/PKC/MEK/ERK-dependent pathway: incidence on peroxisome, mitochondria, and lipid profiles. *Molecules* 2019; 24: 3310.